Investigating how CD200 signaling affects immune cell interactions in stroke.
CD200 signaling mediates the interactions of neurons and endothelia with circulating leukocytes in stroke
This study is looking at how a protein called CD200 can help calm down the immune system after a stroke, which might reduce brain damage and improve recovery.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Sci Ctr Houston NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11092785 on NIH RePORTER |
What this research studies
This research explores the role of CD200 signaling in the immune response following a stroke. It aims to understand how CD200 interacts with its receptor on immune cells to potentially reduce harmful immune activation that can worsen brain injury. By manipulating CD200 and its receptor in mouse models, the study will assess how these interactions influence the behavior of immune cells and the extent of stroke damage. The findings could lead to new therapeutic strategies to protect the brain after a stroke.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who have experienced a stroke.
Not a fit: Patients who have not had a stroke or are under 21 years old may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that minimize brain damage and improve recovery after a stroke.
How similar studies have performed: Previous research has shown promise in targeting immune responses in stroke, suggesting that this approach could yield significant insights.
Where this research is happening
Houston, United States
- University of Texas Hlth Sci Ctr Houston — Houston, United States (Active)
Researchers
- Principal investigator: Liu, Fudong — University of Texas Hlth Sci Ctr Houston
- Study coordinator: Liu, Fudong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.